Evidence map›Paper›PMID 40727310›Full record

ArticleTransboundary and emerging diseases2025

Emergence of a PRRSV Strain Recombined From Two Modified-Live Virus Vaccines and Its Elimination From a Breeding Herd.

Giovani Trevisan, Joel Sparks, Michael Zeller, Hao Tong, Ganwu Li, Jianqiang Zhang, Phillip C Gauger, Christopher Rademacher, Rodger Main, Ana Paula Poeta Silva and 1 more

Abstract read
In one paragraph

Article in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Giovani TrevisanVeterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, Iowa, USA.ORCID https://orcid.org/0000-0002-4980-526X
Joel SparksAMVC, Frankfort, Indiana, USA.
Michael ZellerVeterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, Iowa, USA.
Hao TongVeterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, Iowa, USA.
Ganwu LiVeterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, Iowa, USA.ORCID https://orcid.org/0000-0002-6370-9573
Jianqiang ZhangVeterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, Iowa, USA.ORCID https://orcid.org/0000-0001-7228-6202
Phillip C GaugerVeterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, Iowa, USA.
Christopher RademacherVeterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, Iowa, USA.
Rodger MainVeterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, Iowa, USA.
Ana Paula Poeta SilvaVeterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, Iowa, USA.
Daniel C L LinharesVeterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, Iowa, USA.ORCID https://orcid.org/0000-0001-7788-9942

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Porcine reproductive and respiratory syndrome (PRRS) is one of the most challenging diseases for swine production. The PRRS virus (PRRSV) is an RNA virus that replicates via an RNA-dependent RNA polymerase (RDRP) mechanism, which is prone to high mutation rates. Recombinations are characterized by the exchange of genetic material across two or more viruses. Modified live virus (MLV) vaccines produce an immune response to PRRSV after replicating in pigs, similar to natural exposure. Here, we report the emergence of an MLV-like recombinant strain, its associated production impact, and its disappearance trajectory from a breeding herd. The emergent virus was identified and successfully eliminated from a 9248-sow breed-to-wean herd. Accidental usage of two distinct MLVs in the herd led to the recombination and emergence of a new strain. The clinical presentation was mild compared to current wild-type strains, with the associated production loss amounting to 549 weaned piglets per 1000 sows. Production levels returned to normal within 7 weeks. Transitory, no significative production loss in the wean-to-market phase was identified. Immunization of the herd and tightening of biosecurity and biocontainment practices were able to eliminate the virus from the herd, without evidence of broad regional spread.

Indexed as

Porcine Reproductive and Respiratory SyndromePorcine respiratory and reproductive syndrome virusRecombination, GeneticViral VaccinesAnimalsFemaleSwineVaccines, AttenuatedVaccines, AttenuatedViral Vaccinesanimal healthgenetic evolutionmanagement practicesproduction lossPRRSVrecombination

Identifiers

PMID40727310
PMCPMC12301085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.